Denali Therapeutics Inc. (DNLI) analyst actions
Rating and price-target actions on DNLI in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the DNLI overview →
1 measured DNLI analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program | Press release | +2.44% | +13.84% |
Keep exploring
More DNLI: earnings → · SEC filings → · DNLI overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Senseonics Holdings, Inc. (SENS) | 318 | -0.44% | 42% |
| Allogene Therapeutics, Inc. (ALLO) | 316 | +0.18% | 51% |
| Myomo Inc. (MYO) | 315 | +0.35% | 54% |
| ICU Medical, Inc. (ICUI) | 313 | +0.02% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.